Obsidian Therapeutics is a biotech company that develops innovative therapies for various diseases. The company is focused on creating novel treatments that can improve patient outcomes and quality of life.

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients.
 
Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.

Located in the heart of Cambridge with a new laboratory facility in Bedford, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work.  We offer competitive salary and benefits, and potential for employee ownership through stock options.

Alexandria Venture Investments

ShangPharma

Amgen Ventures

Atlas Venture

Takeda Ventures

Vertex Ventures

Vertex Ventures HC

Google Ventures

Bristol-Myers Squibb

Samsara BioCapital

Logos Capital

RA Capital Management

Deep Track Capital

Surveyor Capital

TCG Crossover

The Column Group

Obsidian Therapeutics

We are proud to announce that we have closed a $160.5 million #SeriesC #financing. Proceeds will be used to support clinical development of OBX-115 in ongoing trials, including a multicenter trial for patients with metastatic melanoma and non-small cell lung cancer.

The financing rounds was led by new investor, Wellington Management. Additional new investors participating in the financing include Foresite Capital, Janus Henderson Investors, Novo Holdings A/S, Paradigm BioCapital, RTW Investments, funds and accounts advised by T. Rowe Price Associates, Inc., and Woodline Partners LP. Existing investors Atlas Venture, Blue Owl Healthcare Opportunities, Bristol Myers Squibb, Deep Track Capital, Logos Capital, RA Capital Management, TCGX, Samsara BioCapital and Surveyor Capital (a Citadel company) also participated in the financing. 

Read the full announcement here: https://lnkd.in/eExbpjBU

Today our CEO, Madan Jagasia, will be joining advanced therapy leaders from across the industry at Deloitte's NextGen Therapies Industry Working Group meeting at Deloitte University. Madan is participating in the panel titled, “Leading with Impact: a CEO Perspective on Strategy, Innovation, and Growth”. #NextGenTherapies #IWG2024

Check it out: Obsidian’s Justin Dunlevy, MBA will be participating in a panel titled “Approaching Cost Effective Methods to Dismantle Challenges for Phase 1/2 Companies,” at the Supply Chain & Logistics for Cell Therapies Summit in Boston.

Learn more here: https://lnkd.in/eKugZE56


Congratulations to Andres Alvarado, Arman Aksoy, Caroline Code, Mary Gribble, Gauri Kulkarni, Sheyla Mirabal, Michelle Ols, and Mercay Reuter on their recent promotions!  Thank you all for the value you bring every day, we look forward to your continued growth and success!

We’re excited to announce that we are presenting initial clinical data from the ongoing first-in-human study of OBX-115 and preclinical data from our cytoDRiVE® platform demonstrating regulatable cytoTIL15 signal transduction in cis and trans, as well as the ability of a single drug-responsive domain (DRD) to coregulate two cytokines, LIGHT and mbIL15, in tumor-infiltrating lymphocytes (TIL) during #AACR, which will be held April 5-10, 2024 in San Diego, CA.

To learn more about the positive data results, read here: https://lnkd.in/eZW89dsH

COM:OBSIDIANTX

Obsidian Therapeutics, Inc.

Analysis Not Available